Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC47H57ClFN7O8S |
InChIKeyNICKHWYZMNLEPJ-TZSMONEZSA-N |
CAS Registry2230821-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 18 Jan 2019 |